FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213073484> ?p ?o ?g. }

• W4213073484 endingPage "516" @default.
• W4213073484 startingPage "516" @default.
• W4213073484 abstract "516 Background: Pembro showed antitumor activity in 1L and 2L for pts with UC in the single-arm, phase 2 KEYNOTE-052 study (NCT02335424) and the randomized phase 3 KEYNOTE-045 (NCT02256436) study, respectively. This post hoc exploratory analysis evaluated whether primary tumor location affected efficacy and safety of pembro (KEYNOTE-052; KEYNOTE-045) and chemotherapy (chemo; KEYNOTE-045). Methods: KEYNOTE-052 enrolled cisplatin-ineligible pts with advanced/metastatic UC who had not previously received systemic therapy; they received pembro (200 mg IV Q3W). KEYNOTE-045 enrolled pts with advanced/metastatic UC who had received platinum-containing chemo; pts were randomly assigned 1:1 to receive pembro (200 mg IV Q3W) or investigator’s choice of chemo (paclitaxel, docetaxel, or vinflunine). Both studies required pts to have measurable disease per RECIST v1.1. Upper tract (UT) UC included primary tumors in the renal pelvis or ureter; lower tract (LT) UC included primary tumors in the bladder or urethra. Pts with UT and LT disease (UT/LT) were classified as LT. Pts receiving pembro were treated until disease progression, unacceptable toxicity, or withdrawal of consent, for up to 2y. End points were PFS, ORR, and DOR per RECIST v1.1 by central radiology assessment and OS. Results: A total of 369 pembro-treated pts (68 UT; 301 LT [79 UT/LT]) from KEYNOTE-052 plus 270 pembro-treated pts (93 UT; 177 LT [33 UT/LT]) and 272 chemo-treated pts (94 UT; 178 LT) from KEYNOTE-045 were evaluated. Median follow-up from randomization to data cutoff (09/26/20 and 10/1/20, respectively) was ≥56 mo. Both studies enrolled a similar percentage of pts with PD-L1–positive tumors (25%-30%). PFS, ORR, DOR, and OS for pembro were consistent regardless of tumor location, although ORR for KEYNOTE-045 was lower for the UT group (Table). In the chemo arm of KEYNOTE-045, similar efficacy was observed regardless of tumor location or regimen. Grade 3-5 TRAEs occurred at similar rates in KEYNOTE-052 (19.1% UT; 21.6% LT) and KEYNOTE-045 (17.2% UT; 16.8% LT). Conclusions: In this exploratory analysis, pembro showed similar clinical activity and manageable safety regardless of primary UC tumor location. Clinical trial information: NCT02256436 and NCT02335424. [Table: see text]" @default.
• W4213073484 created "2022-02-24" @default.
• W4213073484 creator A5012800133 @default.
• W4213073484 creator A5018398274 @default.
• W4213073484 creator A5021997880 @default.
• W4213073484 creator A5024147987 @default.
• W4213073484 creator A5026717218 @default.
• W4213073484 creator A5031088617 @default.
• W4213073484 creator A5033220136 @default.
• W4213073484 creator A5035439869 @default.
• W4213073484 creator A5039709555 @default.
• W4213073484 creator A5041610986 @default.
• W4213073484 creator A5050042851 @default.
• W4213073484 creator A5063838757 @default.
• W4213073484 creator A5064884168 @default.
• W4213073484 creator A5071418777 @default.
• W4213073484 creator A5073970384 @default.
• W4213073484 creator A5074756323 @default.
• W4213073484 creator A5075327765 @default.
• W4213073484 creator A5082741754 @default.
• W4213073484 creator A5082742595 @default.
• W4213073484 creator A5082815940 @default.
• W4213073484 date "2022-02-20" @default.
• W4213073484 modified "2023-09-23" @default.
• W4213073484 title "Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials." @default.
• W4213073484 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.516" @default.
• W4213073484 hasPublicationYear "2022" @default.
• W4213073484 type Work @default.
• W4213073484 citedByCount "0" @default.
• W4213073484 crossrefType "journal-article" @default.
• W4213073484 hasAuthorship W4213073484A5012800133 @default.
• W4213073484 hasAuthorship W4213073484A5018398274 @default.
• W4213073484 hasAuthorship W4213073484A5021997880 @default.
• W4213073484 hasAuthorship W4213073484A5024147987 @default.
• W4213073484 hasAuthorship W4213073484A5026717218 @default.
• W4213073484 hasAuthorship W4213073484A5031088617 @default.
• W4213073484 hasAuthorship W4213073484A5033220136 @default.
• W4213073484 hasAuthorship W4213073484A5035439869 @default.
• W4213073484 hasAuthorship W4213073484A5039709555 @default.
• W4213073484 hasAuthorship W4213073484A5041610986 @default.
• W4213073484 hasAuthorship W4213073484A5050042851 @default.
• W4213073484 hasAuthorship W4213073484A5063838757 @default.
• W4213073484 hasAuthorship W4213073484A5064884168 @default.
• W4213073484 hasAuthorship W4213073484A5071418777 @default.
• W4213073484 hasAuthorship W4213073484A5073970384 @default.
• W4213073484 hasAuthorship W4213073484A5074756323 @default.
• W4213073484 hasAuthorship W4213073484A5075327765 @default.
• W4213073484 hasAuthorship W4213073484A5082741754 @default.
• W4213073484 hasAuthorship W4213073484A5082742595 @default.
• W4213073484 hasAuthorship W4213073484A5082815940 @default.
• W4213073484 hasConcept C121608353 @default.
• W4213073484 hasConcept C126322002 @default.
• W4213073484 hasConcept C126894567 @default.
• W4213073484 hasConcept C141071460 @default.
• W4213073484 hasConcept C143998085 @default.
• W4213073484 hasConcept C2776694085 @default.
• W4213073484 hasConcept C2777701055 @default.
• W4213073484 hasConcept C2780057760 @default.
• W4213073484 hasConcept C2780352672 @default.
• W4213073484 hasConcept C2781190966 @default.
• W4213073484 hasConcept C2910384678 @default.
• W4213073484 hasConcept C2911057145 @default.
• W4213073484 hasConcept C3019882237 @default.
• W4213073484 hasConcept C31760486 @default.
• W4213073484 hasConcept C512399662 @default.
• W4213073484 hasConcept C535046627 @default.
• W4213073484 hasConcept C71924100 @default.
• W4213073484 hasConceptScore W4213073484C121608353 @default.
• W4213073484 hasConceptScore W4213073484C126322002 @default.
• W4213073484 hasConceptScore W4213073484C126894567 @default.
• W4213073484 hasConceptScore W4213073484C141071460 @default.
• W4213073484 hasConceptScore W4213073484C143998085 @default.
• W4213073484 hasConceptScore W4213073484C2776694085 @default.
• W4213073484 hasConceptScore W4213073484C2777701055 @default.
• W4213073484 hasConceptScore W4213073484C2780057760 @default.
• W4213073484 hasConceptScore W4213073484C2780352672 @default.
• W4213073484 hasConceptScore W4213073484C2781190966 @default.
• W4213073484 hasConceptScore W4213073484C2910384678 @default.
• W4213073484 hasConceptScore W4213073484C2911057145 @default.
• W4213073484 hasConceptScore W4213073484C3019882237 @default.
• W4213073484 hasConceptScore W4213073484C31760486 @default.
• W4213073484 hasConceptScore W4213073484C512399662 @default.
• W4213073484 hasConceptScore W4213073484C535046627 @default.
• W4213073484 hasConceptScore W4213073484C71924100 @default.
• W4213073484 hasIssue "6_suppl" @default.
• W4213073484 hasLocation W42130734841 @default.
• W4213073484 hasOpenAccess W4213073484 @default.
• W4213073484 hasPrimaryLocation W42130734841 @default.
• W4213073484 hasRelatedWork W2754795980 @default.
• W4213073484 hasRelatedWork W2772794544 @default.
• W4213073484 hasRelatedWork W2808310746 @default.
• W4213073484 hasRelatedWork W2993719401 @default.
• W4213073484 hasRelatedWork W3007356240 @default.
• W4213073484 hasRelatedWork W3028814175 @default.
• W4213073484 hasRelatedWork W3135333393 @default.
• W4213073484 hasRelatedWork W3185379225 @default.
• W4213073484 hasRelatedWork W4212855179 @default.
• W4213073484 hasRelatedWork W4213073484 @default.

• next